Publikasi Scopus FKUI 2021 per tanggal 31 Agustus 2021 (582 artikel)

Irdam G.A., Febriyani, Rasyid N., Taher A.
57194729795;57226319849;56245069300;7005269743;
A systematic review of intracavernosal injection of mesenchymal stem cells for diabetic erectile dysfunction
2021
Medical Journal of Indonesia
30
2
96
105
1
Department of Urology, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
Irdam, G.A., Department of Urology, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Febriyani, Department of Urology, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Rasyid, N., Department of Urology, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Taher, A., Department of Urology, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
BACKGROUND As current erectile dysfunction (ED) treatments are limited, other treatment such as stem cells should be explored. Hence, this study aimed to review the sources, method of administration, and therapeutic effect of mesenchymal stem cells (MSCs) for diabetic ED treatment. METHODS All relevant articles regarding the use of MSCs for diabetic ED were searched in PubMed and Google Scholar databases from December 15, 2019 to January 1, 2020 published in the past 10 years. The keywords were “mesenchymal stem cells” and “diabetic ED”. The selection and critical appraisal of the studies were discussed. Diabetic ED was evaluated for functional and structural outcome. Functional outcome in animal studies was assessed by intracavernosal pressure/mean arterial pressure (ICP/ MAP) ratio, meanwhile the structural outcome was done microscopically. In human study, the assessments were done using international index of erectile function score (IIEF-5) to erection hardness score and penile Doppler ultrasonography. RESULTS There were 10 animal studies and 3 human studies. The studies used MSCs from adipose (n = 6), bone marrow (n = 4), placenta (n = 1), umbilical cord (n = 1), and muscle tissue (n = 1). The MSCs were administrated through intracavernosal injection in all studies. In all animal studies, functional outcome was improved, shown in higher ICP/MAP ratio. Microscopically, there were an increase of cavernosal endothelial cells, vascular endothelial growth factor, nitric oxide synthase, and smooth muscle cells. In human studies, IIEF-5 and erection hardness score were improved. Peak systolic velocity was also higher. CONCLUSIONS MSCs may be a promising therapy for diabetic ED; however, long-term safety concerns still need further investigations. © 2021, Faculty of Medicine, Universitas Indonesia. All rights reserved.
Diabetes mellitus; Erectile dysfunction; Mesenchymal stem cells
arterial pressure; Article; body mass; bone marrow; data extraction; DNA damage; Doppler ultrasonography; echography; erectile dysfunction; genomic instability; hardness; histochemistry; human; insulin sensitivity; International Index of Erectile Function; intracavernous pressure; mesenchymal stem cell; nonhuman; peak systolic velocity; placenta; questionnaire; shock wave therapy; smooth muscle cell; systematic review; umbilical cord
Faculty of Medicine, Universitas Indonesia
8531773
Article
Q4
164
21905